Abstract：
Cefiderocol is a novel siderophore-conjugated cephalosporin with a catechol residue acting as an iron chelator. Cefiderocol forms a chelating complex with ferric iron and is transported rapidly into bacterial cells through iron-uptake systems. As a result, cefiderocol shows good activity against Gram-negative bacteria, including carbapenem-resistant isolates that are causing significant global health issues. Cefiderocol has been approved for clinical use in the United States and Europe, where it is being used to treat infection caused by carbapenem-resistant Gram-negative pathogens.
摘要：
头孢多醇是一种新型的铁载体偶联的头孢菌素，其儿茶酚残基充当铁螯合剂。头孢地洛与三价铁形成螯合络合物，并通过铁摄取系统迅速转运到细菌细胞中。因此,头孢地洛对革兰氏阴性细菌显示出良好的活性，包括碳青霉烯类耐药的分离株，这些分离株正在引起重大的全球健康问题。Cefiderocol已在美国和欧洲被批准用于临床使用，用于治疗耐碳青霉烯革兰氏阴性病原体引起的感染。
